Ege David S. 4
4 · Seres Therapeutics, Inc. · Filed Aug 19, 2024
Insider Transaction Report
Form 4
Ege David S.
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-08-15+2,969→ 78,703 total - Sale
Common Stock
2024-08-16$0.84/sh−1,128$948→ 77,575 total - Exercise/Conversion
Restricted Stock Units
2024-08-15−2,969→ 29,688 total→ Common Stock (2,969 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.